CD8A and neoplasm: When combined with anti-cytotoxic T-lymphocyte antigen-4 (anti-CTLA-4) treatment, it was shown to reduce of Treg cells and increase of CD8+ T cells infiltration at the tumor site and consequently elevate the survival rate in a mouse model 51.